Evidence map›Paper›PMID 33815793›Full record

ArticleMolecular and clinical oncology2021

Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report.

Toshinari Yagi, Harumi Nakamura, Toru Wakamatsu, Yoshinori Imura, Hironari Tamiya, Hideaki Sabe, Katsunari Yamashita, Makiyo Watanabe, Satoshi Takenaka

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Toshinari YagiDepartment of Outpatient Chemotherapy, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Harumi NakamuraDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Toru WakamatsuDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Yoshinori ImuraDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hironari TamiyaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hideaki SabeDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Katsunari YamashitaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Makiyo WatanabeDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Satoshi TakenakaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Osaka Medical Center for Cancer and Cardiovascular Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiosarcoma is a rare sarcoma with a poor prognosis and is prone to disseminated intravascular coagulation (DIC), where DIC often interferes with chemotherapy. Primary angiosarcoma of the breast (PASB) is a type of angiosarcoma that is located in mammary parenchyma and is not associated with radiation exposure. The current study reported a 47-year-old female with DIC associated with PASB. The DIC of the patient relapsed during mono-chemotherapy with paclitaxel (PTX) after first-line anticoagulant therapy using thrombomodulin-α. The second-line danaparoid sodium therapy, followed by self-subcutaneous injection of unfractionated heparin calcium (UFH), resulted in long-term stabilization of DIC. Under this second-line anticoagulant therapy, the patient continued chemotherapy and chemoradiotherapy for >13 months in the outpatient setting without impairment of quality of life. The present case suggested that self-subcutaneous injections of UFH may be a useful therapeutic option for long-term control of DIC associated with PASB. However, further prospective clinical trails are needed to verify the efficacy of self-subcutaneous injection of UFH in similar settings.

Indexed as

angiosarcomadisseminated intravascular coagulationheparin

Identifiers

PMID33815793
PMCPMC8010513
OpenAlexW3139241880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.